Asia branded business decline due to shipment push-outs
Asia branded sales declined 8% YoY in Q2 due to supplies pushed to next quarter; recovery depends on execution.
medium · management_commentary
Ajanta Pharma Limited — Q2 FY24
Ajanta Pharma delivered a solid Q2 FY24 with consolidated revenue of INR 1,028 crore (+10% YoY) and EBITDA of INR 291 crore (+48% YoY), driven by strong US generics growth (+28%...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Africa market slowdown may persist
Africa branded business saw a slowdown in the market over the last 4-5 months; growth recovery is uncertain.
medium · management_commentaryChantix launch timing uncertain
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
medium · analyst_questionPrice erosion in US generics remains high single-digit
Management confirmed high single-digit price erosion in US base portfolio, which could pressure margins if volumes don't compensate.
medium · analyst_question